Therapeutics development in myotonic dystrophy type 1
- 4 March 2011
- journal article
- review article
- Published by Wiley in Muscle & Nerve
- Vol. 44 (2), 160-169
- https://doi.org/10.1002/mus.22090
Abstract
Myotonic dystrophy (DM1), the most common adult muscular dystrophy, is a multisystem, autosomal dominant genetic disorder caused by an expanded CTG repeat that leads to nuclear retention of a mutant RNA and subsequent RNA toxicity. Significant insights into the molecular mechanisms of RNA toxicity have led to the previously unforeseen possibility that treating DM1 is a viable prospect. In this review, we briefly present the clinical picture in DM1, and describe how the research in understanding the pathogenesis of RNA toxicity in DM1 has led to targeted approaches to therapeutic development at various steps in the pathogenesis of the disease. We discuss the promise and current limitations of each with an emphasis on RNA‐based therapeutics and small molecules. We conclude with a discussion of the unmet need for clinical tools and outcome measures that are essential prerequisites to proceed in evaluating these potential therapies in clinical trials. Muscle Nerve, 2011Keywords
This publication has 84 references indexed in Scilit:
- Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophyNature Structural & Molecular Biology, 2010
- Progress in therapeutic antisense applications for neuromuscular disordersEuropean Journal of Human Genetics, 2009
- Rational and Modular Design of Potent Ligands Targeting the RNA That Causes Myotonic Dystrophy 2ACS Chemical Biology, 2009
- Dynamic Combinatorial Selection of Molecules Capable of Inhibiting the (CUG) Repeat RNA−MBNL1 Interaction In Vitro: Discovery of Lead Compounds Targeting Myotonic Dystrophy (DM1)Journal of the American Chemical Society, 2008
- Conserved GU-Rich Elements Mediate mRNA Decay by Binding to CUG-Binding Protein 1Molecular Cell, 2008
- MicroRNAs in Disease and Potential Therapeutic ApplicationsMolecular Therapy, 2007
- Increased Steady-State Levels of CUGBP1 in Myotonic Dystrophy 1 Are Due to PKC-Mediated HyperphosphorylationMolecular Cell, 2007
- Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophyProceedings of the National Academy of Sciences of the United States of America, 2006
- Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophyNature Genetics, 2006
- Muscleblind proteins regulate alternative splicingThe EMBO Journal, 2004